Previous close | 0.2500 |
Open | 0.2500 |
Bid | 0.0000 |
Ask | 0.2000 |
Strike | 62.50 |
Expiry date | 2023-12-15 |
Day's range | 0.2500 - 0.2500 |
Contract range | N/A |
Volume | |
Open interest | 165 |
In this article, we will be taking a look at the 25 most valuable European companies heading into 2024. To skip our detailed analysis, you can go directly to see the 5 most valuable European companies heading into 2024. Europe is considered to be the most advanced region in the world, especially in terms of standard […]
Kymera (KYMR) receives a $15 million milestone payment from Sanofi as dosing begins in a phase II study evaluating KT-474 for treating atopic dermatitis. Shares rise on the same.
U.S. officials met with manufacturers of the infant and toddler RSV immunization Beyfortus this week seeking to boost access to the shot, the White House said in a statement on Thursday after senior Biden administration officials met with the companies last week. The officials on Tuesday met with representatives of Sanofi , AstraZeneca and Thermo Fisher "and urged them to work expeditiously to meet demand for immunizations this winter season through the commercial market," the White House said in a statement.